trending Market Intelligence /marketintelligence/en/news-insights/trending/tcpzk0_o-z0wx1icqz_8ea2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

US FDA grants priority review to Portola's drug application for betrixaban

Lithium Sector - Production and Supply Outlook

Connected Car Connectivity Growing As Cars Get Smarter

State Of Indonesian Online Video: Subscription

Virtual Multichannel Revenues Projected To Soar In Next Five Years


US FDA grants priority review to Portola's drug application for betrixaban

The U.S. FDA granted priority review to Portola Pharmaceuticals Inc.'s new drug application for betrixaban.

Betrixaban, an FDA-designated fast track investigational drug, is a Factor Xa inhibitor anticoagulant for extended-duration prophylaxis of venous thromboembolism in acute medically ill patients with risk factors for venous thromboembolism.

A priority review shortens the agency's review timeline to six months from the standard review period of 10 months. The application for the drug was deemed sufficiently complete to allow a substantive review and was given an approval date of June 24, 2017.

In addition, the European Medicines Agency has validated Portola's marketing authorization application for betrixaban. The EMA's committee for medicinal products for human use is reviewing the application under a standard 210-day review period.